6/10/2023

Janusmed kön och genus

Janusmed kön och genus – Brilique

Janusmed kön och genus är ett kunskapsstöd som tillhandahåller information om köns- och genusaspekter på läkemedelsbehandling. Kunskapsstödet är avsedd främst för hälso- och sjukvårdspersonal. Texterna är generella och ska inte ses som behandlingsriktlinjer. Det är alltid behandlande läkare som ansvarar för patientens medicinering.

För att komma till startsidan för Janusmed kön och genus och för att göra sökningar klicka här.

Tillbaka till index
A A
A A

Tikagrelor

Tikagrelor

Klass: A

Visa all info

Skriv ut

Kontakta oss

Produkter

Brilique

Brilique
ATC-koder

B01AC24

B01AC24
Substanser

tikagrelor

tikagrelor
Sammanfattning

I de stora studier som jämfört tikagrelor med klopidogrel eller placebo hos patienter med kranskärlsjukdom (PLATO och PEGASUS-TIMI 54) sågs ingen könsskillnad avseende effekt på primära händelser eller allvarlig blödning.

I de stora studier som jämfört tikagrelor med klopidogrel eller placebo hos patienter med kranskärlsjukdom (PLATO och PEGASUS-TIMI 54) sågs ingen könsskillnad avseende effekt på primära händelser eller allvarlig blödning.
Background

Pharmacokinetics and dosing
Following a single 200 mg dose of ticagrelor in healthy patients, women had 37% higher AUC and 52% higher Cmax than men. The mean half-life was 22% longer in women than in men. However, these differences are not considered to be clinically important [1-3]. No dose adjustment based on sex is necessary [1-3].

Effects
A large sex-specific meta-analysis of randomized phase III and IV trials compared the efficacy of P2Y12 inhibitors (prasugrel, ticagrelor, cangrelor) with clopidogrel or placebo in patients with coronary artery disease (63 346 men, 24 494 women). The potent P2Y12 inhibitors reduced the risk of major adverse cardiovascular events similarly in men and women [4]. This finding was confirmed in a recent sex-specific meta-analysis of P2Y12 inhibitors (ticagrelor, prasugrel, clopidogrel) in patients with acute coronary syndrome [5]. The meta-analyses included two large trials on ticagrelor, one compared ticagrelor and clopidogrel in patients with acute coronary syndrome (PLATO) and one compared ticagrelor and placebo in patients with myocardial in......

Visa hela bakgrundstexten

# Pharmacokinetics and dosing Following a single 200 mg dose of ticagrelor in healthy patients, women had 37% higher AUC and 52% higher Cmax than men. The mean half-life was 22% longer in women than in men. However, these differences are not considered to be clinically important [1-3]. No dose adjustment based on sex is necessary [1-3]. # Effects A large sex-specific meta-analysis of randomized phase III and IV trials compared the efficacy of P2Y12 inhibitors (prasugrel, ticagrelor, cangrelor) with clopidogrel or placebo in patients with coronary artery disease (63 346 men, 24 494 women). The potent P2Y12 inhibitors reduced the risk of major adverse cardiovascular events similarly in men and women [4]. This finding was confirmed in a recent sex-specific meta-analysis of P2Y12 inhibitors (ticagrelor, prasugrel, clopidogrel) in patients with acute coronary syndrome [5]. The meta-analyses included two large trials on ticagrelor, one compared ticagrelor and clopidogrel in patients with acute coronary syndrome (PLATO) and one compared ticagrelor and placebo in patients with myocardial infarction (PEGASUS-TIMI 54). No significant sex differences were observed for the primary efficacy endpoint (cardiovascular death, myocardial infarctions, or stroke) [6, 7]. # Adverse effects A sex-specific meta-analysis (63 346 men, 24 494 women) examining the risk of major bleeding from treatment with P2Y12 inhibitors (prasugrel, ticagrelor, cangrelor) in coronary artery disease suggested no significant difference in major bleeding in men and women [4, 6, 7] # Reproductive health issues Regarding teratogenic aspects, please consult Janusmed Drugs and Birth Defects (in Swedish, Janusmed fosterpåverkan).
Försäljning på recept

Visa hela försäljning på recept

Fler män än kvinnor hämtade ut tabletter innehållande tikagrelor (ATC-kod B01AC24) på recept i Sverige år 2017, totalt 17 442 män och 6 601 kvinnor. Det motsvarar 3,5 respektive 1,3 personer per tusen invånare. Andelen som hämtat ut läkemedel var högst i åldersgruppen 75-84 år hos båda könen. I genomsnitt var tabletter innehållande tikagrelor 3,3 gånger vanligare hos män [8].
Referenser

Visa referenser

  1. Teng R. Pharmacokinetic, pharmacodynamic and pharmacogenetic profile of the oral antiplatelet agent ticagrelor. Clin Pharmacokinet. 2012;51:305-18.

  2. Brilique (prasugrel). Summary of Product Charateristics. European Medicines Agency (EMA). [updated 2018-05-30, cited 2019-01-22].

  3. Brilinta (ticagrelor). DailyMed [www]. US National Library of Medicine. [updated 2018-03-09, cited 2019-01-22].

  4. Lau ES, Braunwald E, Murphy SA, Wiviott SD, Bonaca MP, Husted S et al. Potent P2Y12 Inhibitors in Men Versus Women: A Collaborative Meta-Analysis of Randomized Trials. J Am Coll Cardiol. 2017;69(12):1549-1559.

  5. Lee KK, Welton N, Shah AS, Adamson PD, Dias S, Anand A et al. Differences in relative and absolute effectiveness of oral P2Y12 inhibition in men and women: a meta-analysis and modelling study. Heart. 2018;104(8):657-664.

  6. Husted S, James SK, Bach RG, Becker RC, Budaj A, Heras M et al. The efficacy of ticagrelor is maintained in women with acute coronary syndromes participating in the prospective, randomized, PLATelet inhibition and patient Outcomes (PLATO) trial. Eur Heart J. 2014;35(23):1541-50.

  7. Bonaca MP, Bhatt DL, Cohen M, Steg PG, Storey RF, Jensen EC et al. Long-term use of ticagrelor in patients with prior myocardial infarction. N Engl J Med. 2015;372(19):1791-800.

  8. Läkemedelsstatistik. Stockholm: Socialstyrelsen. 2017 [cited 2019-01-30.]

  1. Teng R. Pharmacokinetic, pharmacodynamic and pharmacogenetic profile of the oral antiplatelet agent ticagrelor. Clin Pharmacokinet. 2012;51:305-18.
  2. Brilique (prasugrel). Summary of Product Charateristics. European Medicines Agency (EMA). [updated 2018-05-30, cited 2019-01-22].
  3. Brilinta (ticagrelor). DailyMed [www]. US National Library of Medicine. [updated 2018-03-09, cited 2019-01-22].
  4. Lau ES, Braunwald E, Murphy SA, Wiviott SD, Bonaca MP, Husted S et al. Potent P2Y12 Inhibitors in Men Versus Women: A Collaborative Meta-Analysis of Randomized Trials. J Am Coll Cardiol. 2017;69(12):1549-1559.
  5. Lee KK, Welton N, Shah AS, Adamson PD, Dias S, Anand A et al. Differences in relative and absolute effectiveness of oral P2Y12 inhibition in men and women: a meta-analysis and modelling study. Heart. 2018;104(8):657-664.
  6. Husted S, James SK, Bach RG, Becker RC, Budaj A, Heras M et al. The efficacy of ticagrelor is maintained in women with acute coronary syndromes participating in the prospective, randomized, PLATelet inhibition and patient Outcomes (PLATO) trial. Eur Heart J. 2014;35(23):1541-50.
  7. Bonaca MP, Bhatt DL, Cohen M, Steg PG, Storey RF, Jensen EC et al. Long-term use of ticagrelor in patients with prior myocardial infarction. N Engl J Med. 2015;372(19):1791-800.
  8. Läkemedelsstatistik. Stockholm: Socialstyrelsen. 2017 [cited 2019-01-30.]
Uppdaterat

Litteratursökningsdatum 1/22/2019

Litteratursökningsdatum 1/22/2019
Se även

Klopidogrel

Prasugrel